Drug news
Generx(Cardium Therapeutics) enters Phase III for Myocardial Ischaemia
The ASPIRE Phase III registration study has been initiated to evaluate the therapeutic effects of Generx (Ad5FGF-4) from Cardium Therapeutics in patients with myocardial ischemia (insufficient blood flow in the heart due to coronary artery disease).The ASPIRE study is a 100-patient, randomized and controlled multi-center study being conducted at up to six leading cardiology centers in the Russian Federation. The study is designed to further evaluate the safety and effectiveness of Cardium's Generx DNA-based angiogenic product candidate, which has already been tested in clinical studies involving 650 patients at more than one hundred medical centers in the U.S., Europe and elsewhere.